For NSCLC , the recommendation for doing PDL1 is only when other molecular testing are negative For EGFR, ALK, KRAS - so if this was not recommended ,you could consider doing this and then consider PDL1. Patients with metastatic NSCLC and PD-L1 expression levels of 1% or more—but who also have a targetable driver oncogene molecular variant (eg, EGFR, ALK, ROS1)—should receive first-line targeted therapy for that oncogene and not first-line immune check point inhibitors like PDL1 , because targeted therapies yield higher response rates . So if you have done other test and they are negative , then the option as you said is right . For patient on Atezolizumab single agent therapy is median survival is about 20months . Please get back to me with the above mentioned molecular testing results .